A detailed history of New York Life Investment Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, New York Life Investment Management LLC holds 38,677 shares of VRTX stock, worth $18 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
38,677
Previous 39,466 2.0%
Holding current value
$18 Million
Previous $18.5 Million 2.76%
% of portfolio
0.19%
Previous 0.2%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$460.0 - $505.78 $362,940 - $399,060
-789 Reduced 2.0%
38,677 $18 Million
Q2 2024

Aug 05, 2024

BUY
$392.81 - $485.53 $157,516 - $194,697
401 Added 1.03%
39,466 $18.5 Million
Q1 2024

May 03, 2024

SELL
$407.69 - $446.08 $547,935 - $599,531
-1,344 Reduced 3.33%
39,065 $16.3 Million
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $2.52 Million - $3.02 Million
-7,342 Reduced 15.38%
40,409 $16.4 Million
Q3 2023

Nov 07, 2023

SELL
$338.18 - $362.46 $488,331 - $523,392
-1,444 Reduced 2.94%
47,751 $16.6 Million
Q2 2023

Aug 04, 2023

SELL
$314.42 - $351.91 $73,888 - $82,698
-235 Reduced 0.48%
49,195 $17.3 Million
Q1 2023

May 08, 2023

SELL
$283.23 - $323.1 $871,215 - $993,855
-3,076 Reduced 5.86%
49,430 $15.6 Million
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $69,153 - $77,798
-242 Reduced 0.46%
52,506 $15.2 Million
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $216,873 - $241,979
-792 Reduced 1.48%
52,748 $15.3 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $12.6 Million - $15.7 Million
53,540 New
53,540 $15.1 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track New York Life Investment Management LLC Portfolio

Follow New York Life Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York Life Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on New York Life Investment Management LLC with notifications on news.